Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Stock Rated "Moderate Buy" by Sell-Side Brokerages

Key Points

• Analyst consensus is “Moderate Buy”: Twelve of 17 analysts rate Structure Therapeutics a buy, while two rate it a strong buy, one a hold and two a sell. The average 12-month price target is $110.91.
• GPCR opened at $35.93, well below its 52-week high of $94.90, and recently reported a quarterly loss of $0.49 per share versus the expected loss of $0.39.
• Institutional investors own 91.78% of the stock. Structure Therapeutics is developing oral medicines, led by the GLP-1 receptor agonist GSBR-1290 for obesity and type 2 diabetes.

Shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Get Free Report) have received an average recommendation of "Moderate Buy" from the seventeen research firms that are presently covering the stock, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, one has issued a hold recommendation, twelve have issued a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $110.91.

Several research analysts have commented on GPCR shares. Wall Street Zen raised Structure Therapeutics from a "strong sell" rating to a "sell" rating in a research report on Monday, August 17th. Weiss Ratings cut Structure Therapeutics from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Friday, September 18th. Citigroup restated a "market outperform" rating on shares of Structure Therapeutics in a research note on Friday, August 7th. Canaccord Genuity Group set a $111.00 target price on shares of Structure Therapeutics in a research note on Friday, August 7th. Finally, Citizens Jmp reissued a "market outperform" rating and issued a $110.00 price target on shares of Structure Therapeutics in a report on Wednesday, September 9th.

Structure Therapeutics Price Performance

GPCR stock opened at $35.93 on Friday. The stock has a market capitalization of $2.50 billion, a price-to-earnings ratio of -35.93 and a beta of -1.45. The company has a 50-day moving average of $46.49 and a two-hundred day moving average of $46.66. Structure Therapeutics has a 52-week low of $24.56 and a 52-week high of $94.90.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.49) EPS for the quarter, missing analysts' consensus estimates of ($0.39) by ($0.10). Equities analysts expect that Structure Therapeutics will post -1.87 EPS for the current fiscal year.

Institutional Investors Weigh In On Structure Therapeutics

Hedge funds have recently made changes to their positions in the stock. Avoro Capital Advisors LLC boosted its holdings in Structure Therapeutics by 21.3% during the fourth quarter. Avoro Capital Advisors LLC now owns 6,555,555 shares of the company's stock valued at $455,939,000 after purchasing an additional 1,150,000 shares in the last quarter. Capitolis Liquid Global Markets LLC acquired a new position in shares of Structure Therapeutics in the 4th quarter worth approximately $61,086,000. Principal Financial Group Inc. raised its holdings in shares of Structure Therapeutics by 36.6% in the 1st quarter. Principal Financial Group Inc. now owns 1,753,764 shares of the company's stock worth $84,531,000 after buying an additional 469,554 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund bought a new position in shares of Structure Therapeutics during the 4th quarter worth approximately $32,535,000. Finally, EcoR1 Capital LLC bought a new position in shares of Structure Therapeutics during the 4th quarter worth approximately $23,256,000. Institutional investors own 91.78% of the company's stock.

About Structure Therapeutics

Structure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing oral medicines for chronic diseases. The company uses its structure-based drug discovery platform to target G protein-coupled receptors (GPCRs), a large class of proteins involved in metabolic, cardiovascular and pulmonary functions.

Its lead program is GSBR-1290, also known as aleniglipron, an oral small-molecule glucagon-like peptide-1 (GLP-1) receptor agonist being developed for conditions including obesity and type 2 diabetes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.